MicroBiome Therapeutics, LLC.

MicroBiome Therapeutics, LLC. focuses on innovative solutions in the biotechnology sector, specifically developing therapeutics that leverage the human microbiome to address various health conditions. Founded in 2009 in Broomfield, US, MicroBiome Therapeutics, LLC. specializes in microbiome-based therapeutics.

The company has undergone significant growth and raised a total of USD 1. 00 mn through various funding rounds, with the most recent being a Series B round on November 1, 2017, involving investors such as Lagniappe Angels, NOLA Angel Network, and Zehnder Communications, Inc. MicroBiome Therapeutics, LLC. offers a range of therapeutic solutions aimed at manipulating the human microbiome to improve health outcomes.

Their products are directed towards both individual consumers and healthcare providers, addressing a variety of health issues through microbiome modulation. The company primarily serves markets in North America and has plans to expand its offerings to international clients. MicroBiome Therapeutics, LLC. generates revenue through the sale of its therapeutic products.

Their revenue model is based on unit sales of developed microbiome therapies. Detailed pricing structures are not publicly disclosed, but their approach may include transaction-based pricing that aligns with specific health solutions offered to clients. MicroBiome Therapeutics, LLC. plans to leverage its recent Series B funding of USD 1.

00 mn to support the development of new microbiome-based therapies. The company is targeting expansion into European and Asian markets by 2025, aiming to introduce innovative products tailored to diverse health conditions. This growth strategy includes enhancing their research capabilities and building partnerships with healthcare organizations to broaden their market reach.